An extension to the company’s Series A brings total funding to €23 million and clears the path for the first human trial of KUP101, a dual TLR agonist targeting solid tumours and drug-resistant infections. Most immunotherapy research in oncology has concentrated on the adaptive immune system, the learned, antibody-generating machinery that checkpoint inhibitors like pembrolizumab […]

This story continues at The Next Web